CRL
Charles River Laboratories
NYSE: CRL · HEALTHCARE · DIAGNOSTICS & RESEARCH
$163.84
-1.77% today
Updated 2026-04-29
Market cap
$8.23B
P/E ratio
—
P/S ratio
2.05x
EPS (TTM)
$-2.90
Dividend yield
—
52W range
$114 – $229
Volume
1.0M
Charles River Laboratories (CRL) Earnings
Quarterly earnings history, analyst estimates, and stock price reaction.
EPS beat streak
8 of 8
Last 8 quarters
Avg EPS surprise
+10.1%
Last 4 quarters
Revenue YoY growth
-0.8%
Most recent quarter
EPS YoY growth
-10.2%
Most recent quarter
Earnings surprise history (last 12 quarters)
Beat estimate Missed estimate
Quarterly EPS and revenue trend
Quarterly revenue EPS (diluted)
How the stock reacts to earnings
Avg 1-day reaction
-3.6%
Last 3 reports
Positive reaction rate
33%
1 of 3 quarters
Largest single-day move
-10.6%
2025-08-06
| Report date | EPS actual | Surprise | Close before | Close after | 1-day reaction |
|---|---|---|---|---|---|
| 2026-02-18 | $2.39 | +1.7% | $158.53 | $164.24 | +3.6% |
| 2025-11-05 | $2.43 | +3.4% | $177.85 | $170.88 | -3.9% |
| 2025-08-06 | $3.12 | +22.4% | $167.49 | $149.78 | -10.6% |
Quarterly earnings history
| Fiscal quarter ending | EPS estimate | EPS actual | Surprise | Revenue | YoY revenue |
|---|---|---|---|---|---|
| 2025-12-31 | $2.35 | $2.39 | +1.7% | $994.23M | -0.8% |
| 2025-09-30 | $2.35 | $2.43 | +3.4% | $1.00B | -0.5% |
| 2025-06-30 | $2.55 | $3.12 | +22.4% | $1.03B | +0.6% |
| 2025-03-31 | $2.07 | $2.34 | +13.0% | $984.17M | -2.7% |
| 2024-12-31 | $2.53 | $2.66 | +5.1% | $1.00B | -1.1% |
| 2024-09-30 | $2.42 | $2.59 | +7.0% | $1.01B | -1.6% |
| 2024-06-30 | $2.39 | $2.80 | +17.2% | $1.03B | -3.2% |
| 2024-03-31 | $2.07 | $2.27 | +9.7% | $1.01B | — |
| 2023-12-31 | $2.40 | $2.46 | +2.5% | $1.01B | — |
| 2023-09-30 | $2.37 | $2.72 | +14.8% | $1.03B | — |
| 2023-06-30 | $2.64 | $2.69 | +1.9% | $1.06B | — |
Frequently asked questions
Has Charles River Laboratories beaten earnings estimates?
Charles River Laboratories has beaten Wall Street EPS estimates in 8 of its last 8 quarterly reports, with an average EPS surprise of +10.1% over the last 4 quarters.
How does CRL stock react to earnings?
CRL stock has moved an average of -3.6% in the trading day following earnings over its last 3 reports, with positive reactions in 33% of those quarters.
What is Charles River Laboratories's revenue growth rate?
Charles River Laboratories reported year-over-year revenue growth of -0.8% in its most recent quarter, with EPS growing -10.2% year-over-year.